Stockreport

Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results

Silence Therapeutics Plc - American Depository Share  (SLN) 
PDF Topline results for Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for third quarter of 2026 LONDON--(BUSINESS WIRE)- [Read more]